NCT03591757View on ClinicalTrials.gov

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions
Transthyretin AmyloidosisAmyloidosis, Leptomeningeal, Transthyretin-Related
Interventions
DRUG

Tolcapone

Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.

Trial Locations (1)

02118

Amyloidosis Center, Boston Medical Center, Boston

Sponsors

Collaborators (1)

Corino Therapeutics, Inc.
All Listed Sponsors
collaborator

Corino Therapeutics, Inc.

INDUSTRY

lead

Boston University

OTHER